The rebranding marks the first phase of Lunit's unified global identity, connecting breast health, AI detection, and precision oncology under one name. SEOUL, South Korea, Nov. 6, 2025 /PRNewswire/ -- ...
- Lunit's strategic global leap: to acquire all of Volpara shares at AUD 1.15 per share, envisioning completion by Q2 2024 SEOUL. South Korea, Dec. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a ...
SEOUL, South Korea and WELLINGTON, New Zealand, Feb. 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, and Volpara Health, a company that offers AI-powered software to help providers better understand cancer risk, ...
Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk prediction, autonomous report generation, and innovations to transform global cancer care SEOUL, South ...
Lunit, a South Korean medical artificial intelligence (AI) startup, said Monday it has won shareholders' approval for the takeover of Volpara Health, a breast cancer solution firm in New Zealand. At a ...
SEATTLE, Aug. 4, 2022 /PRNewswire/ -- Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX: VHT), a global health technology software leader providing an integrated platform for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback